UPDATE 1-J&J posts results above estimates, nudges forecast up
Oct 15 (Reuters) - Johnson & Johnson reported better than expected quarterly results on strong growth for its prescription drugs, including new treatments for cancer and to prevent blood clots, and the company slightly raised its full-year profit forecast.
The diversified healthcare company on Tuesday reported net earnings of $2.98 billion, or $1.04 per share, for the third quarter. That compared with $2.97 billion, or $1.05 per share, in the year-earlier period.
Excluding special items, J&J earned $1.36 per share. Analysts on average, had expected $1.32 per share, according to Thomson Reuters I/B/E/S.
Global company sales rose 3.1 percent to $17.58 billion, above Wall Street expectations of $17.46 billion.
J&J said it expects earnings this year, excluding special items, of $5.44 per share to $5.49 per share, up from its prior view of $5.40 to $5.47.